Some patients find that taking their dose earlier in the day is helpful, though there is no established clinical evidence that retatrutide has a direct stimulatory effect on sleep
Preexisting motility disorders (e.g., diabetic gastroparesis, scleroderma, severe GERD) heighten risk, and symptoms can linger even after stopping
Fatigue typically resolves by week six to eight, replaced by improved energy as weight loss progresses and sleep quality improves
You give your GLP-1 receptors time to adapt so nausea stays manageable and weight loss results build steadily
While semaglutide activates only the GLP-1 receptor, tirzepatide is a dual agonist that activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors
Available from: Liao C, Liang X, Zhang X, Li Y (2023) The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: a systematic review and meta-analysis